Chemistry:SR-31742A
SR-31742A, or SR-31742, is a sigma receptor modulator which was under development for the treatment of schizophrenia and manic episodes but was never marketed.[1][2][3][4][5] Its route of administration is unknown.[1]
The drug is selective for the sigma receptors and shows high affinity for 3-PPP-labeled sigma receptors (Ki = 5.3 nM).[3] Its selectivity for the sigma σ1 versus σ2 receptor is unknown, though it is known to have high affinity for the sigma σ1 receptor specifically.[4] Whether SR-31742A is an agonist or antagonist of the sigma σ1 receptor is said to be unknown,[4] though it has been described as an antagonist in some publications.[5] The drug reduces the hyperlocomotion induced by dextroamphetamine and various other drugs without affecting spontaneous locomotor activity in rodents.[4][3]
SR-31742A was under development by Sanofi-Synthelabo.[1][2] It reached phase 2 clinical trials for both schizophrenia and manic episodes prior to the discontinuation of its development in 2001.[1][2]
See also
- List of investigational antipsychotics
- List of investigational bipolar disorder drugs
- Panamesine
References
- ↑ 1.0 1.1 1.2 1.3 "SR 31742A". 9 March 2001. https://adisinsight.springer.com/drugs/800002053.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on SR-31742A with Synapse". 30 May 2026. https://synapse.patsnap.com/drug/145847779070495588f7bd4c5154a728.
- ↑ 3.0 3.1 3.2 "Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A". Neuropharmacology 32 (6): 605–615. June 1993. doi:10.1016/0028-3908(93)90057-a. PMID 8336824.
- ↑ 4.0 4.1 4.2 4.3 "Pharmacology and therapeutic potential of sigma(1) receptor ligands". Current Neuropharmacology 6 (4): 344–366. December 2008. doi:10.2174/157015908787386113. PMID 19587856.
- ↑ 5.0 5.1 "sigma Receptor antagonists block the development of sensitization to cocaine". European Journal of Pharmacology 296 (2): 123–128. January 1996. doi:10.1016/0014-2999(95)00693-1. PMID 8838447.
 |  |
